In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

A diabetes associated HNF1B polymorphism increases risk of prevalent diastolic dysfunction in two independent Swedish population cohorts

Session Diastolic function

Speaker John Molvin

Event : ESC Congress 2016

  • Topic : heart failure
  • Sub-topic : Diastolic Ventricular Dysfunction
  • Session type : Moderated Posters

Authors : J Molvin (Lund,SE), PM Nilsson (Malmö,SE), M Leosdottir (Lund,SE), U Lindblad (Gothenburg,SE), B Daka (Gothenburg,SE), L Bennet (Malmö,SE), L Rastam (Malmö,SE), O Melander (Malmö,SE), V Lyssenko (Lund,SE), M Magnusson (Lund,SE)

Authors:
J. Molvin1 , P.M. Nilsson2 , M. Leosdottir1 , U. Lindblad3 , B. Daka3 , L. Bennet2 , L. Rastam2 , O. Melander2 , V. Lyssenko4 , M. Magnusson1 , 1Skane University Hospital, Department of Cardiology, Skåne University Hospital Malmö - Lund - Sweden , 2Department of Clinical Sciences, Lund University, Skåne University Hospital - Malmö - Sweden , 3University of Gothenburg, Institute of Medicine, Department of Public Health and Community Medicine, Sahlgrenska Academy - Gothenburg - Sweden , 4Lund University, Department of Clinical Sciences, Diabetes and Endocrinology, Diabetes Center, Malmö Sweden. - Lund - Sweden ,

On behalf: HARVEST - HeARt and brain failure inVESTigation study group

Citation:
European Heart Journal ( 2016 ) 37 ( Abstract Supplement ), 814

Background: Although diabetes, hyperglycemia and insulin resistance increase risk of future cardiovascular disease (CVD), earlier genetic studies have failed to show associations between diabetes-related single-nucleotide polymorphisms (SNPs) and CVD-risk.

Purpose: To examine if 43 SNPs with earlier established genome wide association with increased risk of type 2 diabetes (T2D), hyperglycemia and insulin resistance were also associated with prevalent early signs of diastolic dysfunction (DD) as measured by echocardiographical examination (UCG) in two independent Swedish population-based cohorts.

Methods: We genotyped 43 SNPs in 43 genes that reported genome-wide significant association with T2D, hyperglycemia and insulin resistance traits, in 1792 subjects from the population-based Malmö Preventive Project (MPP) with full UCG data (mean age 68 years; 29% women, 36% prevalent T2D) (discovery cohort) and in 996 subjects from the VARA cohort with full UCG data (mean age 51 years, 52% women, 7% prevalent T2D) (replication cohort). Logistic regression was used to adjust for covariates (age, sex, systolic and diastolic blood pressure, hypertensive treatment and diabetes status).

Results: In the fully adjusted logistic regression analysis of the MPP cohort common variants in 4 genes were significantly associated (p<0.05) with increased risk of prevalent DD: ADAMTS9 (Odds ratio (OR), 1.22, p=0.045), HNF1B (OR, 1.21, p=0.028), JAZF1 (OR, 1.18, p=0.044), TSPAN8 (OR, 1.25, p=0.023) and common variants in 4 genes were associated with decreased risk of prevalent DD: HNF1A (OR, 0.77; p=0.011), KLF14 (OR, 0.85, p=0.044), TCF7L2 (OR, 0.81, p=0.018), NOTCH2 (OR, 0.72, p=0.021). When these 8 SNPs were tested in the replication cohort only one SNP reached nominal significant association with DD in the fully adjusted logistic regression analysis; HNF1B rs757210 (OR, 1.38, p=0.042).

Conclusion: Here we show that an identified in GWAS T2D susceptibility locus HNF1B is also associated with increased risk of prevalent DD as measured by UCG in two independent Swedish cohorts.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are